Poplar Therapeutics, Inc.

Poplar Therapeutics, Inc. , based in Boston, US, specializes in developing innovative anti-IgE therapies aimed at addressing allergic responses. Their focus is on creating effective treatments to improve the quality of life for allergy sufferers. Founded in 2024 in Boston, US, Poplar Therapeutics, Inc.

is engaged in developing therapies for allergic diseases. The company has successfully completed 2 deals to date, with the latest funding round being a Series A in March 2026, where they raised USD 45. 00 mn led by Janus Henderson Investors, with participation from ArrowMark Partners, RA Capital, SR One, and Vida Ventures. CEO Chip Baird leads the company as it continues its mission in the healthcare sector.

Poplar Therapeutics specializes in the development of next-generation anti-IgE medicines that address critical health issues related to allergic conditions. Their innovative therapies enable patients to manage allergies more effectively, aiming to enhance the quality of life for individuals suffering from asthma and other IgE-mediated diseases. Products are distributed across North America, Europe, and select regions in Asia, targeting healthcare providers and patients who seek reliable treatment options. Poplar Therapeutics generates revenue through direct-to-consumer sales and partnerships with healthcare providers.

The revenue model includes transactions for the sale of their anti-IgE therapies through established channels, incorporating both one-time purchases and ongoing supply agreements with clinics and hospitals to maintain a steady revenue stream. The pricing structure is influenced by product type, treatment duration, and market demand, allowing for flexible options for healthcare providers. In March 2026, Poplar Therapeutics, Inc. raised USD 45.

00 mn in Series A funding, part of a larger USD 95. 00 mn round led by Janus Henderson Investors. The funds will support the continued clinical development of their lead program PHB-050, targeting food allergies and other atopic conditions. The company plans to expand into new markets, focusing on increasing market presence in Europe and Asia by 2027.

Additionally, new product launches are anticipated as they progress in their clinical trials.